| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the W. M. Keck Center for Transgene Research and Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana
Clinical studies have indicated that high plasma levels of fibrinogen, or decreased fibrinolytic potential, are conducive to an increased risk of cardiovascular disease. Other investigations have shown that insoluble fibrin promotes atherosclerotic lesion formation by affecting smooth muscle cell proliferation, collagen deposition, and cholesterol accumulation. To directly assess the physiological impact of an imbalanced fibrinolytic system on both early and late stages of this disease, mice deficient for plasminogen activator inhibitor-1 (PAI-1-/-) were used in a model of vascular injury/repair, and the resulting phenotype compared to that of wild-type (WT) mice. A copper-induced arterial injury was found to generate a lesion with characteristics similar to many of the clinical features of atherosclerosis. Fibrin deposition in the injured arterial wall at early (7 days) and late (21 days) times after copper cuff placement was prevalent in WT mice, but was greatly diminished in PAI-1-/- mice. A multilayered neointima with enhanced collagen deposition was evident at day 21 in WT mice. In contrast, only diffuse fibrin was identified in the adventitial compartments of arteries from PAI-1-/- mice, with no evidence of a neointima. Neovascularization was observed in the adventitia and was more extensive in WT arteries, relative to PAI-1-/- arteries. Additionally, enhanced PAI-1 expression and fat deposition were seen only in the arterial walls of WT mice. The results of this study emphasize the involvement of the fibrinolytic system in vascular repair processes after injury and indicate that alterations in the fibrinolytic balance in the vessel wall have a profound effect on the development and progression of vascular lesion formation.
This article has been cited by other articles:
 |
|
 |
|
  R. L.C. Hoo, W.S. Chow, M.H. Yau, A. Xu, A. W.K. Tso, H.F. Tse, C. H.Y. Fong, S. Tam, L. Chan, and K. S.L. Lam Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2777 - 2782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. P. Fay, N. Garg, and M. Sunkar Vascular Functions of the Plasminogen Activation System Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1231 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wan, N. Shukla, A. P.C. Yim, J. L. Johnson, G. D. Angelini, and J. Y. Jeremy Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 494 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Schafer, M. R. Schroeter, C. Dellas, M. Puls, M. Nitsche, E. Weiss, G. Hasenfuss, and S. V. Konstantinides Plasminogen Activator Inhibitor-1 From Bone Marrow-Derived Cells Suppresses Neointimal Formation After Vascular Injury in Mice Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1254 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Xu, R. D. Balsara, N. V. Gorlatova, D. A. Lawrence, F. J. Castellino, and V. A. Ploplis Conservation of Critical Functional Domains in Murine Plasminogen Activator Inhibitor-1 J. Biol. Chem., April 23, 2004; 279(17): 17914 - 17920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kerlin, B. C. Cooley, B. H. Isermann, I. Hernandez, R. Sood, M. Zogg, S. B. Hendrickson, M. W. Mosesson, S. Lord, and H. Weiler Cause-effect relation between hyperfibrinogenemia and vascular disease Blood, March 1, 2004; 103(5): 1728 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Ploplis, R. Balsara, M. J. Sandoval-Cooper, Z. J. Yin, J. Batten, N. Modi, D. Gadoua, D. Donahue, J. A. Martin, and F. J. Castellino Enhanced in Vitro Proliferation of Aortic Endothelial Cells from Plasminogen Activator Inhibitor-1-deficient Mice J. Biol. Chem., February 13, 2004; 279(7): 6143 - 6151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Sobel, D. J. Taatjes, and D. J. Schneider Intramural Plasminogen Activator Inhibitor Type-1 and Coronary Atherosclerosis Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 1979 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Savov, D. M. Brass, K. G. Berman, E. McElvania, and D. A. Schwartz Fibrinolysis in LPS-induced chronic airway disease Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L940 - L948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bot, J. H. von der Thusen, M. M.P.C. Donners, A. Lucas, M. L. Fekkes, S. C.A. de Jager, J. Kuiper, M. J.A.P. Daemen, T. J.C. van Berkel, S. Heeneman, et al. Serine Protease Inhibitor Serp-1 Strongly Impairs Atherosclerotic Lesion Formation and Induces a Stable Plaque Phenotype in ApoE-/- Mice Circ. Res., September 5, 2003; 93(5): 464 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Konstantinides, K. Schafer, and D. J. Loskutoff Do PAI-1 and Vitronectin Promote or Inhibit Neointima Formation?: The Exact Role of the Fibrinolytic System in Vascular Remodeling Remains Uncertain Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 1943 - 1945. [Full Text] [PDF]
|
|
|
|
|
|
V. de Waard, E. K. Arkenbout, P. Carmeliet, V. Lindner, and H. Pannekoek Plasminogen Activator Inhibitor 1 and Vitronectin Protect Against Stenosis in a Murine Carotid Artery Ligation Model Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 1978 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Schafer, S. Konstantinides, C. Riedel, T. Thinnes, K. Muller, C. Dellas, G. Hasenfuss, and D. J. Loskutoff Different Mechanisms of Increased Luminal Stenosis After Arterial Injury in Mice Deficient for Urokinase- or Tissue-Type Plasminogen Activator Circulation, October 1, 2002; 106(14): 1847 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yuan, L. Liao, D. A. Tulis, and J. Xu Steroid Receptor Coactivator-3 Is Required for Inhibition of Neointima Formation by Estrogen Circulation, June 4, 2002; 105(22): 2653 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Peng, N. Bhatia, A. C. Parker, Y. Zhu, and W. P. Fay Endogenous Vitronectin and Plasminogen Activator Inhibitor-1 Promote Neointima Formation in Murine Carotid Arteries Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 934 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Luttun, F. Lupu, E. Storkebaum, M. F. Hoylaerts, L. Moons, J. Crawley, F. Bono, A. R. Poole, P. Tipping, J.-M. Herbert, et al. Lack of Plasminogen Activator Inhibitor-1 Promotes Growth and Abnormal Matrix Remodeling of Advanced Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice Arterioscler. Thromb. Vasc. Biol., March 1, 2002; 22(3): 499 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C.Y. Chan, D. A. Duszczyszyn, F. J. Castellino, and V. A. Ploplis Accelerated Skin Wound Healing in Plasminogen Activator Inhibitor-1-Deficient Mice Am. J. Pathol., November 1, 2001; 159(5): 1681 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Edelstein, K. Nakajima, D. Pfaffinger, and A. M. Scanu Oxidative events cause degradation of apoB-100 but not of apo[a] and facilitate enzymatic cleavage of both proteins J. Lipid Res., October 1, 2001; 42(10): 1664 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhu, P. M. Farrehi, and W. P. Fay Plasminogen Activator Inhibitor Type 1 Enhances Neointima Formation After Oxidative Vascular Injury in Atherosclerosis-Prone Mice Circulation, June 26, 2001; 103(25): 3105 - 3110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. PLOPLIS and F. J. CASTELLINO Attenuation of Neointima Formation Following Arterial Injury in PAI-1 Deficient Mice Ann. N.Y. Acad. Sci., June 1, 2001; 936(1): 466 - 468. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
